Cookie, an 8-week-old Pitbull mix puppy, diagnosed with parvovirus, faced a grim prognosis, a highly contagious and deadly disease among dogs.
Image Credit - Instagram
Parvovirus primarily affects young puppies who haven't received their full vaccinations, with a staggering 91% mortality rate if untreated.
Image Credit - Instagram
Historically, parvo treatment focused on symptom management and couldn't combat the virus itself, leading to challenging decisions for pet owners.
Image Credit - Instagram
Elanco Animal Health Inc. developed the first-ever targeted treatment for canine parvovirus, offering hope and improved survival rates.
Image Credit - Instagram
Elanco's Canine Parvovirus Monoclonal Antibody treatment received conditional approval and directly fights the virus by blocking its entry into host cells.
Image Credit - Instagram
Clinical trials showed that zero dogs treated with Elanco's Monoclonal Antibody died, shortening the disease's course and increasing survivability.
Image Credit - Instagram
The treatment is administered intravenously in a single dose, resolving symptoms more quickly and reducing hospitalizations.
Image Credit - Instagram
Veterinarians at The Fix Project clinic, one of the first to use Elanco's treatment, reported increased success rates and shorter treatment periods.
Image Credit - Instagram
The new treatment not only benefits animals but also relieves the emotional toll on veterinary teams by providing more positive outcomes.
Image Credit - Instagram
Cookie, the first puppy to receive Elanco's Monoclonal Antibody, made a remarkable recovery within days, demonstrating the treatment's effectiveness in real-life scenarios.
Image Credit - Instagram